2025-10-06
Researchers from NUS Medicine have developed a novel RNA-based therapy that could transform treatment for metabolic dysfunction-associated steatohepatitis (MASH), previously known as Non-alcoholic fatty liver disease (NAFLD), which affects approximately 25% of people worldwide, and up to 40% of adults in Singapore.
